Claims

1. Use of a compound in the manufacture of a medicament for the treatment of diabetic foot-associated bacterial infections or other bacterial infections of the foot associated with peripheral ischemia, wherein the compound is {6-[(1*E*)-3-{methyl[(3-methyl-1-benzofuran-2-yl)methyl]amino}-3-oxoprop-1-en-1-yl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2*H*)-yl}methyl dihydrogen phosphate or a pharmaceutically acceptable salt or metabolite or pharmaceutically acceptable salt of a metabolite thereof, wherein said metabolite is (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8,-tetrahydro-1,8-napthyridin-3-yl)acrylamide.

2. The use according to claim 1, wherein the bacterial infection is caused by a Staphylococcal species including but not limited to *Staphylococcus aureus*.

3. The use according to claim 1 or 2, wherein the bacterial infection is caused by methicillin-resistant *Staphylococcus aureus*.

4. The use according to claim 1, 2 or 3, wherein the bacterial infection is an infection of soft tissue and/or bone tissue.

5. The use according to claim 1, 2, 3 or 4, wherein the bacterial infection is osteomyelitis.

6. The use according to claim 1, 2, 3, 4 or 5, wherein the compound is the bis-ethanolammonium salt of {6-[(1*E*)-3-{methyl[(3-methyl-1-benzofuran-2-yl)methyl]amino}-3-oxoprop-1-en-1-yl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2*H*)-yl}methyl dihydrogen phosphate.

7. The use according to claim 1, 2, 3, 4, 5 or 6, wherein the compound is to be administered at a dosage of 5 mg/day to 600 mg/day, preferably 40 mg/day to 720 mg/day, more preferably 80 mg/day to 480 mg/day, most preferably 16 mg/day to 480 mg/day.

8. The use according to claim 7, wherein the compound is to be administered intravenously twice daily, each administration being in a dosage of 40 mg to 160 mg.

9. The use according to claim 7, wherein the compound is to be administered orally twice daily, each administration being in a dosage of 40 mg to 240 mg.

10. The use according toclaim 7, wherein the compound is to be administered intravenously three times daily, each administration being in a dosage of 40 mg to 240 mg.

11. The use according to claim 7, wherein the compound is to be administered orally three times daily , each administration being in a dosage of 40 mg to 240 mg

12. The use according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 wherein infected and/or necrotic tissue is to be removed prior to, simultaneously with and/or after said compound is to be administered.

13. The use according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, wherein the medicament is to be administered with one or more further antibiotic agents or antibacterial agents.

14. Use of a pharmaceutical composition in the manufacture of a medicament for treating diabetic foot-associated bacterial infections or other bacterial infections of the foot associated with peripheral ischemia, wherein the composition comprises the compound specified in claim 1 or 6 above and the use is according to one or more of claims 1 to 5 and 7 to 13.